MCID: SHR001
MIFTS: 52

Short Bowel Syndrome

Categories: Rare diseases, Gastrointestinal diseases, Fetal diseases, Genetic diseases

Aliases & Classifications for Short Bowel Syndrome

MalaCards integrated aliases for Short Bowel Syndrome:

Name: Short Bowel Syndrome 12 72 49 36 51 41 14 69
Acquired Short Bowel Syndrome 12
Short Gut Syndrome 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10605
MeSH 41 D012778
NCIt 46 C99059
KEGG 36 H01469
UMLS 69 C0036992

Summaries for Short Bowel Syndrome

NIH Rare Diseases : 49 Short bowel syndrome is a disorder characterized by malabsorption of nutrients due to problems involving the small intestine. The small intestine is the tube-shaped organ between the stomach and large intestine, which includes the duodenum, jejunum, and ileum, where most food digestion and nutrient absorption take place. The causes of short bowel syndrome in adults include Crohn disease, mesenteric ischemia, radiation enteritis, or surgical removal of half or more of the small intestine to treat intestinal diseases or injuries. In children the main causes include necrotizing enterocolitis, intestinal atresias, and intestinal volvulus. Signs and symptoms may include diarrhea, cramping, bloating, heartburn, dehydration, malnutrition, weight loss, food sensitivities, weakness, and fatigue. Examples of treatment include diet and nutritional support, intestinal surgeries, and, in some cases, intestinal transplantation. Last updated: 6/22/2017

MalaCards based summary : Short Bowel Syndrome, also known as acquired short bowel syndrome, is related to congenital short bowel syndrome and intestinal pseudoobstruction, neuronal, chronic idiopathic, x-linked, and has symptoms including postoperative nausea and vomiting and pain, postoperative. An important gene associated with Short Bowel Syndrome is CLMP (CXADR Like Membrane Protein), and among its related pathways/superpathways are Signaling by GPCR and Focal Adhesion. The drugs Ursodeoxycholic acid and Lactulose have been mentioned in the context of this disorder. Affiliated tissues include liver, small intestine and kidney, and related phenotype is growth/size/body region.

Wikipedia : 72 Short bowel syndrome (SBS, or simply short gut) is a malabsorption disorder caused by a lack of... more...

Related Diseases for Short Bowel Syndrome

Diseases in the Short Bowel Syndrome family:

Congenital Short Bowel Syndrome Secondary Short Bowel Syndrome

Diseases related to Short Bowel Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 125)
# Related Disease Score Top Affiliating Genes
1 congenital short bowel syndrome 34.4 CLMP FLNA
2 intestinal pseudoobstruction, neuronal, chronic idiopathic, x-linked 33.4 CLMP FLNA
3 gastrointestinal system disease 29.1 CCK GCG PYY SST
4 body mass index quantitative trait locus 11 28.4 CCK GCG IGF1 PYY
5 secondary short bowel syndrome 12.0
6 gastroschisis 11.2
7 intestinal pseudo-obstruction 10.9
8 atresia of small intestine 10.8
9 primary optic atrophy 10.4 FLNA GCG
10 pancreatic islet cell tumors 10.3 NTS SST
11 vipoma 10.3 NTS SST
12 pancreatoblastoma 10.3 NTS SST
13 zollinger-ellison syndrome 10.2 NTS SST
14 postcholecystectomy syndrome 10.2 CCK SST
15 liver disease 10.2
16 postgastrectomy syndrome 10.1 NTS PYY SST
17 functional gastric disease 10.1 CCK SST
18 steatorrhea 10.1 CCK SST
19 lactic acidosis 10.1
20 pancreatic cholera 10.1 CCK GCG SST
21 chronic ulcer of skin 10.0 EGF TTR
22 rasmussen encephalitis 10.0 CCK SST
23 acidophil adenoma 10.0 IGF1 SST
24 pain agnosia 10.0 CCK NTS
25 crohn's disease 10.0
26 pituitary infarct 10.0 IGF1 SST
27 hormone producing pituitary cancer 10.0 IGF1 SST
28 pituitary adenoma 1, multiple types 10.0 IGF1 SST
29 burns 10.0 HGF TTR
30 gastroesophageal reflux 10.0 CCK NTS PYY
31 hyperpituitarism 10.0 IGF1 SST
32 enterocolitis 9.9
33 autoinflammation with infantile enterocolitis 9.9
34 perinatal necrotizing enterocolitis 9.9
35 dumping syndrome 9.9 GCG NTS PYY SST
36 mucositis 9.9
37 diarrhea 9.9
38 cholestasis 9.9
39 fibrosis of extraocular muscles, congenital, 1 9.8
40 infantile liver failure syndrome 1 9.8
41 hepatitis 9.8
42 encephalopathy 9.8
43 donohue syndrome 9.8 EGF IGF1
44 endocrine pancreas disease 9.8 GCG IGF1 SST
45 constipation 9.8 CCK FLNA PYY SST
46 glucose metabolism disease 9.8 GCG IGF1 SST
47 overnutrition 9.8 GCG IGF1 PYY
48 hyperglycemia 9.8 GCG IGF1 SST
49 duodenogastric reflux 9.8 CCK NTS PYY SST
50 acrodermatitis enteropathica, zinc-deficiency type 9.7

Graphical network of the top 20 diseases related to Short Bowel Syndrome:



Diseases related to Short Bowel Syndrome

Symptoms & Phenotypes for Short Bowel Syndrome

UMLS symptoms related to Short Bowel Syndrome:


postoperative nausea and vomiting, pain, postoperative

MGI Mouse Phenotypes related to Short Bowel Syndrome:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.23 FLNA HGF IGF1 NTS PYY SST

Drugs & Therapeutics for Short Bowel Syndrome

Drugs for Short Bowel Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
2
Lactulose Approved Phase 4 4618-18-2 11333
3
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
4 glucagon Phase 4,Phase 1,Phase 2
5 Glucagon-Like Peptide 1 Phase 4,Phase 2,Phase 1
6 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
7
Bilirubin Phase 4,Phase 2,Phase 3 635-65-4 5280352
8 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
9 Hormones Phase 4,Phase 3,Phase 2,Phase 1
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
11 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1
12 Fat Emulsions, Intravenous Phase 4,Phase 2,Phase 3,Phase 1
13 Parenteral Nutrition Solutions Phase 4,Phase 3,Phase 2,Phase 1
14 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
15 Soybean oil, phospholipid emulsion Phase 4,Phase 3,Phase 2,Phase 1
16 Incretins Phase 4,Phase 2,Phase 1
17 Cholagogues and Choleretics Phase 4
18 Fibrinolytic Agents Phase 4
19 Plasminogen Phase 4
20 Tissue Plasminogen Activator Phase 4
21 N-Methylaspartate Phase 4
22 Dipeptidyl-Peptidase IV Inhibitors Phase 4
23 HIV Protease Inhibitors Phase 4
24 Hypoglycemic Agents Phase 4,Phase 2
25
protease inhibitors Phase 4
26 Sitagliptin Phosphate Phase 4
27 Soy Bean Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
28 alanine Nutraceutical Phase 4
29 Aspartic Acid Nutraceutical Phase 4
30 glutamine Nutraceutical Phase 4
31 Olive Nutraceutical Phase 4,Phase 3
32 Phytosterol Nutraceutical Phase 4
33
Ampicillin Approved, Vet_approved Phase 2, Phase 3 69-53-4 6249
34
Clindamycin Approved, Vet_approved Phase 2, Phase 3 18323-44-9 29029
35
Metronidazole Approved Phase 2, Phase 3 443-48-1 4173
36
Piperacillin Approved Phase 2, Phase 3 66258-76-2 43672
37
Tazobactam Approved Phase 2, Phase 3 89786-04-9 123630
38
Loperamide Approved Phase 3 53179-11-6 3955
39 Anti-Bacterial Agents Phase 2, Phase 3
40 Antibiotics, Antitubercular Phase 2, Phase 3
41 Anti-Infective Agents Phase 2, Phase 3
42 Antiparasitic Agents Phase 2, Phase 3
43 Antiprotozoal Agents Phase 2, Phase 3
44 Antitubercular Agents Phase 2, Phase 3
45 beta-Lactamase Inhibitors Phase 2, Phase 3
46 Clindamycin palmitate Phase 2, Phase 3
47 Clindamycin phosphate Phase 2, Phase 3
48 Gentamicins Phase 2, Phase 3
49 Penicillanic Acid Phase 2, Phase 3
50 Piperacillin, tazobactam drug combination Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 88)

# Name Status NCT ID Phase Drugs
1 Short Bowel Syndrome and Teduglutide Versus Placebo Completed NCT02099084 Phase 4 Teduglutide;Placebo
2 The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Short Bowel Syndrome Patients Completed NCT01974336 Phase 4 ursodeoxycholic acid
3 rtPA in in the Prevention of CVAD-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome Completed NCT02355743 Phase 4 rtPA lock therapy
4 rHGH and Intestinal Permeability in Intestinal Failure Completed NCT01380366 Phase 4 Somatropin
5 The Use of DPP-4 Inhibitors in Short Bowel Syndrome Recruiting NCT02653131 Phase 4 Dipeptidyl peptidase-4 inhibitor
6 SMOFLipid in Intralipid Intolerant Recruiting NCT03054948 Phase 4 SMOFLipid;Standard therapy
7 Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS) Terminated NCT00742157 Phase 4 Growth Hormone
8 Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion Terminated NCT02476994 Phase 4 Clinolipid;Intralipid
9 Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome Withdrawn NCT01818648 Phase 4 Exenatide;Placebo
10 Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome Completed NCT00169637 Phase 3 rhGH
11 Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition Completed NCT02682381 Phase 3 Teduglutide 0.05mg/kg;Teduglutide 0.025 mg/kg
12 Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Completed NCT00081458 Phase 3 Placebo;Teduglutide 0.05 mg/kg/d;Teduglutide 0.1 mg/kg/d
13 Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects Completed NCT00798967 Phase 3 teduglutide;placebo
14 A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Completed NCT01952080 Phase 3 teduglutide
15 Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS) Completed NCT00930644 Phase 3 teduglutide
16 Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458) Completed NCT00172185 Phase 3 teduglutide 0.05 mg/kg/d;teduglutide 0.10 mg/kg/d
17 A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021 Completed NCT01560403 Phase 3 Teduglutide
18 Impact of SPN on Infection Rate, Duration of Mechanical Ventilation & Rehabilitation in ICU Patients Completed NCT00802503 Phase 3
19 Antibiotic Safety (SCAMP) Completed NCT01994993 Phase 2, Phase 3 ampicillin and metronidazole and gentamicin;ampicillin and gentamicin and clindamycin;gentamicin and Piperacillin- tazobactam;standard of care antibiotics and metronidazole;metronidazole, clindamycin, or piperacillin-tazobactam
20 A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302 Recruiting NCT03268811 Phase 3 Teduglutide
21 Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome (SBS) Who Completed TED-C14-006 Recruiting NCT02954458 Phase 3 Teduglutide
22 Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study Recruiting NCT02949362 Phase 3 Teduglutide
23 Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support Recruiting NCT02980666 Phase 3 Teduglutide
24 Cholestasis Reversal: Efficacy of IV Fish Oil Recruiting NCT00910104 Phase 2, Phase 3 Omegaven®
25 Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children Recruiting NCT01194063 Phase 3 Omega-3 fish oil lipid emulsion
26 Compassionate Use of Omegaven in Children Recruiting NCT02370251 Phase 2, Phase 3 Omegaven
27 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome (SBS) Active, not recruiting NCT02340819 Phase 3 Teduglutide
28 Safety and Efficacy Study in Infant With SBS Active, not recruiting NCT02865122 Phase 2, Phase 3 NTRA-9620;Placebo
29 Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates Not yet recruiting NCT03387579 Phase 3 Lipid Emulsions, Intravenous;Intralipid, 20% Intravenous Emulsion
30 Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study Terminated NCT02266849 Phase 3 Loperamide;Placebo
31 A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals Withdrawn NCT02242656 Phase 3 Opium Tincture USP Deodorized;Opium Tincture USP Deodorized
32 A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001 Withdrawn NCT02246816 Phase 3 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
33 Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease Unknown status NCT01739517 Phase 2 Omegaven Therapy
34 Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants? Unknown status NCT00793195 Phase 2 Intralipid 20%;SMOFlipid 20%
35 Mechanisms of Adaptation in Human Short Bowel Syndrome Completed NCT00248573 Phase 1, Phase 2
36 A Phase 2 Trial Testing ZP1848 in Patients With SBS Completed NCT02690025 Phase 2 ZP1848
37 Diet/Growth Factor Mechanisms of Gut Adaptation Completed NCT00067860 Phase 2 recombinant human growth hormone
38 Use of Pancreatic Enzymes in Short Bowel Syndrome Recruiting NCT03097029 Phase 2 Pancreatic Enzyme
39 Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS) Recruiting NCT03371862 Phase 2 Liraglutide Pen Injector [Victoza]
40 Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis Recruiting NCT02148146 Phase 1, Phase 2 Omegaven
41 Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury Recruiting NCT01845116 Phase 2 Omegaven®
42 Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support Not yet recruiting NCT03415594 Phase 1, Phase 2 FE203799 GLP-2 analogue;FE203799 Placebo GLP-2 analogue
43 Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency Not yet recruiting NCT03408132 Phase 1, Phase 2 FE203799
44 Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure Terminated NCT01573286 Phase 1, Phase 2 Glucagon-Like Peptide 2;Glucagon like peptide-2
45 Trial of 70% Ethanol Versus Heparin to Reduce the Rate of Central Line Infections in Children With Short Bowel Syndrome Withdrawn NCT01263574 Phase 2 70% ethanol
46 Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease Withdrawn NCT01191177 Phase 1, Phase 2 Lovaza (omega-3-acid ethyl ester)
47 Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome Completed NCT00767364 Phase 1
48 Effects of Teduglutide on Cardiac Repolarisation and Conduction in Healthy Male and Female Volunteers Completed NCT01028924 Phase 1 Teduglutide
49 Cholestasis Prevention: Efficacy of IV Fish Oil Completed NCT00512629 Phase 1 Omegaven;Intralipid
50 Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome Unknown status NCT00673751 GLP-2;Placebo

Search NIH Clinical Center for Short Bowel Syndrome

Cochrane evidence based reviews: short bowel syndrome

Genetic Tests for Short Bowel Syndrome

Anatomical Context for Short Bowel Syndrome

MalaCards organs/tissues related to Short Bowel Syndrome:

38
Liver, Small Intestine, Kidney, Colon, Bone, Testes, Skin

Publications for Short Bowel Syndrome

Articles related to Short Bowel Syndrome:

(show top 50) (show all 664)
# Title Authors Year
1
Duodenal lengthening in an adult with ultra-short bowel syndrome. A case report. ( 29106286 )
2018
2
Nutritional therapy complications in children with ultra-short bowel syndrome include growth deficiency but not cholestasis. ( 29405447 )
2018
3
Energy intake in short bowel syndrome: assessment by 24-h dietary recalls compared with the doubly labelled water method. ( 29268807 )
2018
4
The protective effect of fish oil lipid emulsions on intestinal failure-associated liver disease in a rat model of short-bowel syndrome. ( 29039050 )
2018
5
Is Serum Methylmalonic Acid a Reliable Biomarker of Vitamin B12 Status in Children with Short Bowel Syndrome: A Case Series. ( 29129351 )
2018
6
Surgical revascularization of the celiac artery for persistent intestinal ischemia in short bowel syndrome. ( 29247810 )
2018
7
Nutritional Therapy in Adult Short Bowel Syndrome Patients with Chronic Intestinal Failure. ( 29413019 )
2018
8
Congenital Short-Bowel Syndrome in an Adult Dog. ( 29310549 )
2018
9
Managing the Adult Patient With Short Bowel Syndrome. ( 29230136 )
2017
10
Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. ( 29127863 )
2017
11
A Pilot Study Comparing 2 Oral Rehydration Solutions in Patients With Short Bowel Syndrome Receiving Home Parenteral Nutrition: A Prospective Double-Blind Randomized Controlled Trial. ( 28662613 )
2017
12
Clinical Report: Intestinal Rehabilitation Programs in the Management of Pediatric Intestinal Failure and Short Bowel Syndrome. ( 28837507 )
2017
13
Anaphylactic shock with methylprednisolone sodium succinate in a child with short bowel syndrome and cow's milk allergy. ( 29149860 )
2017
14
Long-Term Results of Serial Transverse Enteroplasty with Neovalve Creation for Extreme Short Bowel Syndrome: Report of Two Cases. ( 28559783 )
2017
15
Oral Feeding Difficulties in Children With Short Bowel Syndrome: A Narrative Review. ( 28521656 )
2017
16
Pediatric Short Bowel Syndrome: Predicting Four-Year Outcome after Massive Neonatal Resection. ( 28719916 )
2017
17
Markers of enteral adaptation in pediatric short bowel syndrome. ( 28510260 )
2017
18
A Twist in the Tale of a Pig Model of Short-Bowel Syndrome. ( 29204506 )
2017
19
Enteral Autonomy with Teduglutide Treatment of Intestinal Failure/Short Bowel Syndrome with Depleted Central Venous Access. ( 28993968 )
2017
20
Effect of Splenectomy to Short Bowel Syndrome in Rats. ( 28659672 )
2017
21
Small bowel dilation in children with short bowel syndrome is associated with mucosal damage, bowel-derived bloodstream infections, and hepatic injury. ( 28689603 )
2017
22
Successful treatment of chronic hepatitis C with ground ledipasvir/sofosbuvir in a patient with Crohn's disease and short bowel syndrome. ( 28783205 )
2017
23
Acrodermatitis enteropathica in a patient with short bowel syndrome. ( 29232432 )
2017
24
Personalized Anticoagulation: Guided Apixaban Dose Adjustment to Compensate for Pharmacokinetic Abnormalities Related to Short-Bowel Syndrome. ( 29395704 )
2017
25
Intensive Nutrition Management in a Patient with Short Bowel Syndrome Who Underwent Bariatric Surgery. ( 28770185 )
2017
26
Prophylactic rtPA in the Prevention of Line-associated Thrombosis and Infection in Short Bowel Syndrome. ( 29135819 )
2017
27
Tissue engineering for the treatment of short bowel syndrome in children. ( 28937976 )
2017
28
The Polish Intestinal Failure Centres' consensus on the use of teduglutide for the treatment of short bowel syndrome. ( 28526379 )
2017
29
Anastomotic ulcers in short bowel syndrome: New suggestions from a multidisciplinary approach. ( 28610705 )
2017
30
Current treatment paradigms in pediatric short bowel syndrome. ( 29280097 )
2017
31
A case of osteomalacia due to deranged mineral balance caused by saccharated ferric oxide and short-bowel syndrome: A case report. ( 28953654 )
2017
32
Reconnection surgery in adult post-operative short bowel syndrome < 100 cm: is colonic continuity sufficient to achieve enteral autonomy without autologous gastrointestinal reconstruction? Report from a single center and systematic review of literature. ( 29182898 )
2017
33
Short Bowel Syndrome: An Uncommon Clinical Entity and a Therapeutic Challenge-Our Experience and Review of Literature. ( 28827911 )
2017
34
Growth Trajectory in Children With Short Bowel Syndrome During the First Two Years of Life. ( 28953527 )
2017
35
Prevalence and risk factors for complications in adult patients with short bowel syndrome receiving long-term home parenteral nutrition. ( 28582806 )
2017
36
Radiographic measurement of intestinal length among children with short bowel syndrome: Retrospective determination remains problematic. ( 28987713 )
2017
37
De Novo Development of Hamartomatous Duodenal Polyps in a Patient With Short Bowel Syndrome During Teduglutide Therapy: A Case Report. ( 28666089 )
2017
38
Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure. ( 29174926 )
2017
39
Generation of an artificial intestine for the management of short bowel syndrome. ( 26867049 )
2016
40
Necrotizing enterocolitis is associated with earlier achievement of enteral autonomy in children with short bowel syndrome. ( 26700691 )
2016
41
Congenital Short Bowel Syndrome due to Absent Midgut. ( 27150813 )
2016
42
The administration of ghrelin improved hepatocellular injury following parenteral feeding in a rat model of short bowel syndrome. ( 27651372 )
2016
43
Extensive Intestinal Resection Triggers Behavioral Adaptation, Intestinal Remodeling and Microbiota Transition in Short Bowel Syndrome. ( 27681910 )
2016
44
Severe Gut Microbiota Dysbiosis Is Associated With Poor Growth in Patients With Short Bowel Syndrome. ( 27406942 )
2016
45
On the horizon: trophic peptide growth factors as therapy for neonatal short bowel syndrome. ( 26810694 )
2016
46
Therapeutic Drug Monitoring of Anti-human Immunodeficiency Virus Drugs in a Patient with Short Bowel Syndrome. ( 27746450 )
2016
47
Effect of Liraglutide Treatment on Jejunostomy Output in Patients With Short Bowel Syndrome: An Open-Label Pilot Study. ( 27875281 )
2016
48
Genetic screening of Congenital Short Bowel Syndrome patients confirms CLMP as the major gene involved in the recessive form of this disorder. ( 27352967 )
2016
49
Management and Complications of Short Bowel Syndrome: an Updated Review. ( 27324885 )
2016
50
Is jejunostomy output nutrient or waste in short bowel syndrome? Experience from six cases. ( 27222428 )
2016

Variations for Short Bowel Syndrome

Expression for Short Bowel Syndrome

Search GEO for disease gene expression data for Short Bowel Syndrome.

Pathways for Short Bowel Syndrome

GO Terms for Short Bowel Syndrome

Cellular components related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 CCK EGF GCG HGF IGF1 PYY
2 platelet alpha granule lumen GO:0031093 9.33 EGF HGF IGF1
3 extracellular region GO:0005576 9.32 CCK EGF FLNA GCG HGF IGF1

Biological processes related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway GO:0007186 9.96 CCK GCG NTS PYY SST
2 negative regulation of apoptotic process GO:0043066 9.84 FLNA GCG HGF IGF1
3 positive regulation of cell proliferation GO:0008284 9.83 CCK EGF HGF IGF1
4 positive regulation of cell migration GO:0030335 9.72 EGF HGF IGF1
5 cell proliferation GO:0008283 9.71 GCG HGF IGF1 PYY
6 activation of MAPK activity GO:0000187 9.54 EGF HGF IGF1
7 positive regulation of peptidyl-threonine phosphorylation GO:0010800 9.51 EGF GCG
8 digestion GO:0007586 9.5 PYY SLC15A1 SST
9 ERK1 and ERK2 cascade GO:0070371 9.49 EGF IGF1
10 positive regulation of DNA binding GO:0043388 9.48 EGF IGF1
11 positive regulation of mitotic nuclear division GO:0045840 9.46 EGF IGF1
12 platelet degranulation GO:0002576 9.46 EGF FLNA HGF IGF1
13 negative regulation of release of cytochrome c from mitochondria GO:0090201 9.43 HGF IGF1
14 myoblast proliferation GO:0051450 9.26 HGF IGF1
15 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.26 CCK EGF HGF IGF1
16 regulation of receptor activity GO:0010469 9.23 CCK GCG HGF IGF1 NTS PYY

Molecular functions related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.33 EGF HGF IGF1
2 neuropeptide hormone activity GO:0005184 9.13 CCK NTS PYY
3 hormone activity GO:0005179 9.1 CCK GCG IGF1 PYY SST TTR

Sources for Short Bowel Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....